Notably, SpiD3 treatment inhibited NFκB activation and exacerbated unfolded cellular protein loads thereby activating the UPR, culminating in the arrest of protein synthesis and robust CLL cytotoxicity. Here, NFKB1 is linked to B-cell chronic lymphocytic leukemia.